Early Detection and Diagnosis

You have full text access to this OnlineOpen article

Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology

  1. Peter J.F. Snijders1,†,
  2. Cornelis J.A. Hogewoning2,†,
  3. Albertus T. Hesselink1,
  4. Johannes Berkhof3,
  5. Feja J. Voorhorst3,
  6. Maaike C.G. Bleeker1,
  7. Chris J.L.M. Meijer1,‡,*

Article first published online: 28 MAR 2006

DOI: 10.1002/ijc.21956

Issue

International Journal of Cancer

International Journal of Cancer

Volume 119, Issue 5, pages 1102–1107, 1 September 2006

Additional Information

How to Cite

Snijders, P. J.F., Hogewoning, C. J.A., Hesselink, A. T., Berkhof, J., Voorhorst, F. J., Bleeker, M. C.G. and Meijer, C. J.L.M. (2006), Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int. J. Cancer, 119: 1102–1107. doi: 10.1002/ijc.21956

Author Information

  1. 1

    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands

  2. 2

    Department of Gynecology and Obstetrics, Albert Schweitzer Hospital, Dordrecht, The Netherlands

  3. 3

    Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands

  1. †

    Peter J.F. Snijders and Cornelis J.A. Hogewoning contributed equally to this work.

  2. ‡

    Fax: ++31-20-444-2964

*Department of Pathology, Vrije Universiteit Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands

Publication History

  1. Issue published online: 5 JUN 2006
  2. Article first published online: 28 MAR 2006
  3. Manuscript Accepted: 10 FEB 2006
  4. Manuscript Received: 25 NOV 2005

Funded by

  • Netherlands Organization for Health and Development (ZonMW). Grant Numbers: 28-2725, 22000147

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (133K)

References

  • 1
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Meijer CJLM, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–9.
    Direct Link:
  • 2
    Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavius and cervical cancer. J Clin Pathol 2002; 55: 244–65.
  • 3
    Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342–50.
  • 4
    Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003; 127: 959–68.
  • 5
    Brink AA, Zielinski GD, Steenbergen RD, Snijders PJ, Meijer CJ. Clinical relevance of human papillomavirus testing in cytopathology. Cytopathology 2005; 16: 7–12.
    Direct Link:
  • 6
    Snijders PJF, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003; 201: 1–6.
    Direct Link:
  • 7
    Van Duin M, Snijders PJ, Schrijnemakers HF, Voorhorst FJ, Rozendaal L, Nobbenhuis MA, van den Brule AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ. Human papillomavirus 16 load in normal and abnomal cervical scrapes: an indicator of CINII/III and viral clearance. Int J Cancer 2002; 98: 590–5.
    Direct Link:
  • 8
    Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer 1994; 69: 167–71.
  • 9
    Bavin PJ, Giles JA, Deery A, Crow J, Griffiths PD, Emery VC, Walker PG. Use of semi-quantitative PCR for human papillomavirus DNA type 16 to identify women with high grade cervical disease in a population presenting with a mildly dyskaryotic smear report. Br J Cancer 1993; 67: 602–5.
  • 10
    Ylitalo N, Sørensen P, Joseffson AM, Magnusson PKE, Andersen PK, Pontén J, Adami HO, Gyllensten UB, Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355: 2194–8.
  • 11
    Schlecht NF, Trevisan A, Duarte-Franco E, Rohan TE, Frency A, Villa LL, Franco EL. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003; 103: 519–24.
    Direct Link:
  • 12
    Swan DC, Tucker RA, Tortolero-Luna G, Follen Mitchell M, Wideroff L, Unger ER, Nisenbaum RA, Reeves WC, Icenogle JP. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999; 37: 1030–4.
  • 13
    Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, Rush BB, Gravitt PE, Schussler JE, Schiffman M. Viral load of human papillomavirus and risk of cervical cancer. Lancet 2002; 360: 228–9.
  • 14
    Sherman ME, Wang SS, Wheeler CM, Rich L, Gravitt PE, Tarone R, Schiffman M. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003; 10: 1038–44.
  • 15
    Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Human papillomavirus type 16 in cervical smears as predictor of high-grade cervical intraepithelial neoplasia. Lancet 1992; 339: 959–60.
  • 16
    Sun CA, Lai HC, Chang CC, Neih S, Yu CP, Chu TY. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol 2001; 83: 95–9.
  • 17
    Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, Andersen PK, Melbye M, Adami HO, Gyllensten UB. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355: 2179–80.
  • 18
    Castle PE, Schiffman M, Wheeler CM. Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. Am J Obst Gynecol 2004; 91: 1590–7.
  • 19
    Castle PE, Schiffman M, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Wacholder S, Lorincz AT. Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1311–14.
  • 20
    Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, van Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94–101.
    Direct Link:
  • 21
    Bulkmans NW, Bleeker MC, Berkhof J, Voorhorst FJ, Snijders PJ, Meijer CJ. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer 2005; 117: 177–81.
    Direct Link:
  • 22
    van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/GP6+-PCR followed by reverse line blot analysis enables rapid and high-throughout identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40: 779–87.
  • 23
    Hogewoning CJ, Bleeker MC, van den Brule AJ, Voorhorst FJ, Snijders PJ, Berkhof J, Westenend PJ, Meijer CJ. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003; 107: 811–6.
    Direct Link:
  • 24
    Hesselink AT, van den Brule AJC, Groothuismink ZM, Molano M, Berkhof J, Meijer CJLM, Snijders PJF. Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens. J Clin Microbiol 2005; 43: 4868–71.
  • 25
    Beskow AH, Gyllensten UB. Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri. Int J Cancer 2002; 101: 526–31.
    Direct Link:
  • 26
    Beskow AH, Moberg M, Gyllensten UB. HLA class II allele control of HPV load in carcinoma in situ of the cervix uteri. Int J Cancer 2005; 117: 510–4.
    Direct Link:
  • 27
    Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004; 112: 854–9.
    Direct Link:
  • 28
    Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005; 92: 891–4.
  • 29
    Berkhof J, Bulkmans NWJ, Bleeker MCG, Bulk S, Snijders PJF, Voorhorst FJ, Meijer CJLM. HPV-type specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev (in press).
  • 30
    Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072–9.
  • 31
    Bais AG, Rebolj M, Snijders PJF, de Schipper FA, van der Meulen DAJ, Verheijen RHM, Voorhorst F, van Ballegooijen M, Meijer CJLM, Helmerhorst TJM. Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int J Cancer 2005; 116: 122–9.
    Direct Link:
  • 32
    Berkhof J, de Bruijne MC, Zielinski GD, Bulkmans NWJ, Rozendaal L, Snijders PJF, Verheijen RHM, Meijer CJLM. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006; 118: 1759–68.
    Direct Link:
View Full Article (HTML) Get PDF (133K)